Obatoclax, a Pan-BCL-2 inhibitor, targets cyclin D1 for degradation to induce antiproliferation in human colorectal carcinoma cells

International Journal of Molecular Sciences

Volumn 18, Issue 1, 2017, Pages

  Or, Chi Hung R ^a,b   Chang, Yachu ^a   Lin, Wei Cheng ^a   Lee, Wee Chyan ^a   Su, Hong Lin ^a   Cheung, Muk Wing ^b   Huang, Chang Po ^b   Ho, Cheesang ^b   Chang, Chia Che ^a,c,d  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b KUANG TIEN GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

Author keywords

Antiproliferation; BH3 (BCL 2 homology 3) mimetics; Colorectal cancer; Cyclin D1; G1 phase arrest; Obatoclax; Proteasomal degradation

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLIN D1; CYCLOHEXIMIDE; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OBATOCLAX; PROTEASOME; RETROVIRUS VECTOR; THREONINE; PROTEIN BCL 2; PYRROLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANTAGONISTS AND INHIBITORS; CARCINOMA; COLORECTAL TUMOR; DRUG EFFECTS; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM;

CARCINOMA; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLIN D1; DOWN-REGULATION; G1 PHASE CELL CYCLE CHECKPOINTS; HCT116 CELLS; HT29 CELLS; HUMANS; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES;

EID: 85008145778     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18010044     Document Type: Article

References (56)

1. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F. Cancer incidence and mortality worldwide sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359-E386. [CrossRef] [PubMed]
2. Bogaert, J., Prenen, H. Molecular genetics of colorectal cancer. Ann. Gastroenterol. 2014, 27, 9-14. [PubMed]
3. Sharma, R.A., Manson, M.M., Gescher, A., Steward, W.P. Colorectal cancer chemoprevention: Biochemical targets and clinical development of promising agents. Eur. J. Cancer 2001, 37, 12-22. [CrossRef]
4. Labianca, R., Nordlinger, B., Beretta, G.D., Brouquet, A., Cervantes, A. On behalf of the ESMO Guidelines Working Group. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann. Oncol. 2010, 21, 70-77. [CrossRef] [PubMed]
5. Hanahan, D., Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674. [CrossRef] [PubMed]
6. Delbridge, A.R., Grabow, S., Strasser, A., Vaux, D.L. Thirty years of BCL-2: Translating cell death discoveries into novel cancer therapies. Nat. Rev. Cancer 2016, 16, 99-109. [CrossRef] [PubMed]
7. Correia, C., Lee, S.H., Meng, X.W., Vincelette, N.D., Knorr, K.L., Ding, H., Nowakowski, G.S., Dai, H., Kaufmann, S.H. Emerging understanding of BCL-2 biology: Implications for neoplastic progression and treatment. Biochim. Biophys. Acta 2015, 1853, 1658-1671. [CrossRef] [PubMed]
8. Schulze-Bergkamen, H., Ehrenberg, R., Hickmann, L., Vick, B., Urbanik, T., Schimanski, C.C., Berger, M.R., Schad, A., Weber, A., Heeger, S., et al. BCL-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J. Gastroenterol. 2008, 14, 3829-3840. [CrossRef] [PubMed]
9. Yang, J.-S., Wang, Z., Lv, C.-Y., Liang, X.L., Sun, M., Guo, Y.-Y., De, W. Prognostic significance of BCL-xL gene expression in human colorectal cancer. Acta Histochem. 2011, 113, 810-814.
10. Henderson-Jackson, E.B., Helm, J., Ghayouri, M., Hakam, A., Nasir, A., Leon, M., Bui, M., Yeatman, T., Coppola, D. Correlation between Mcl-1 and pAKT protein expression in colorectal cancer. Int. J. Clin. Exp. Pathol. 2010, 3, 768-774. [PubMed]
11. Goard, C.A., Schimmer, A.D. An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid. 2013, 8, 15-26. [CrossRef] [PubMed]
12. Delbridge, A.R.D., Strasser, A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015, 22, 1071-1080. [CrossRef] [PubMed]
13. Pandey, M.K., Prasad, S., Tyagi, A.K., Deb, L., Huang, J., Karelia, D.N., Amin, S.G., Aggarwal, B.B. Targeting cell survival proteins for cancer cell death. Pharmaceuticals 2016, 9, E11. [CrossRef] [PubMed]
14. Lieber, J., Armeanu-Ebinger, S., Fuchs, J. The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma. Int. J. Mol. Sci. 2015, 16, 4190-4208. [CrossRef] [PubMed]
15. Vela, L., Marzo, I. BCL-2 family of proteins as drug targets for cancer chemotherapy: The long way of BH3 mimetics from bench to bedside. Curr. Opin. Pharmacol. 2015, 23, 74-81. [CrossRef] [PubMed]
16. Croce, C.M., Reed, J.C. Finally, an apoptosis-targeting therapeutics for cancer. Cancer Res. 2016, 76, 1-7. [CrossRef] [PubMed]
17. Konopleva, M., Watt, J., Contractor, R., Tsao, T., Harris, D., Estrov, Z., Bornmann, W., Kantarjian, H., Viallet, J., Samudio, I., et al. Mechanisms of antileukemic activity of the novel BCL-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008, 68, 3413-3420. [CrossRef] [PubMed]
18. Rahmani, M., Aust, M.M., Attkisson, E., Williams, D.C., Jr., Ferreira-Gonzalez, A., Grant, S. Inhibition of BCL-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 2012, 119, 6089-6098. [CrossRef] [PubMed]
19. Xie, C., Edwards, H., Caldwell, J.T., Wang, G., Taub, J.W., Ge, Y. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol. Oncol. 2015, 9, 409-421. [CrossRef] [PubMed]
20. Nguyen, M., Marcellus, R.C., Roulston, A., Watson, M., Serfass, L., Madiraju, S.R.M., Goulet, D., Viallet, J., Bélec, L., Billot, X., et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA 2007, 104, 19512-19517. [CrossRef] [PubMed]
21. Koehler, B.C., Jassowicz, A., Scherr, A.L., Lorenz, S., Radhakrishnan, P., Kautz, N., Elssner, C., Weiss, J., Jaeger, D., Schneider, M., et al. Pan-BCL-2 inhibitor obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. BMC Cancer 2015, 15, 919. [CrossRef] [PubMed]
22. Schwartz-Roberts, J.L., Shajahan, A.N., Cook, K.L., Wärri, A., Abu-Asab, M., Clarke, R. GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D-and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells. Mol. Cancer Ther. 2013, 12, 448-459. [CrossRef] [PubMed]
23. Stamelos, V.A., Fisher, N., Bamrah, H., Voisey, C., Price, J.C., Farrell, W.E., Redman, C.W., Richardson, A. The BH3 mimetic obatoclax accumulates in lysosomes and causes their alkalinization. PLoS ONE 2016, 11, e0150696. [CrossRef] [PubMed]
24. Basit, F., Cristofanon, S., Fulda, S. Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ. 2013, 20, 1161-1173. [CrossRef] [PubMed]
25. Zhong, D., Gu, C., Shi, L., Xun, T., Li, X., Liu, S., Yu, L. Obatoclax induces G1/G0-phase arrest via p38/p21waf1/Cip1 signaling pathway in human esophageal cancer cells. J. Cell Biochem. 2014, 115, 1624-1635. [CrossRef] [PubMed]
26. Koehler, B.C., Scherr, A.L., Lorenz, S., Elssner, C., Kautz, N., Welte, S., Jaeger, D., Urbanik, T., Schulze-Bergkamen, H. Pan-BCL-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS ONE 2014, 9, e106571. [CrossRef] [PubMed]
27. Musgrove, E.A., Caldon, C.E., Barraclough, J., Stone, A., Sutherland, R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11, 558-572. [CrossRef] [PubMed]
28. Qie, S., Diehl, J.A. Cyclin D1, cancer progression, and opportunities in cancer treatment. J. Mol. Med. 2016. [CrossRef] [PubMed]
29. Klein, E.A., Assoian, R.K. Transcriptional regulation of the cyclin D1 gene at a glance. J. Cell Sci. 2008, 121, 3853-3857. [CrossRef] [PubMed]
30. Alao, J.P. The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol. Cancer 2007, 6, 24. [CrossRef] [PubMed]
31. Diehl, J.A., Cheng, M., Roussel, M.F., Sherr, C.J. Glycogen synthase kinase-3_ regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12, 3499-3511. [CrossRef] [PubMed]
32. Okabe, H., Lee, S.H., Phuchareon, J., Albertson, D.G., McCormick, F., Tetsu, O. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS ONE 2006, 1, e128. [CrossRef] [PubMed]
33. Kim, M.K., Park, G.H., Eo, H.J., Song, H.M., Lee, J.W., Kwon, M.J., Koo, J.S., Jeong, J.B. Tanshinone I induces cyclin D1 proteasomal degradation in an ERK1/2 dependent way in human colorectal cancer cells. Fitoterapia 2015, 101, 162-168. [CrossRef] [PubMed]
34. Thoms, H.C., Dunlop, M.G., Stark, L.A. p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer Res. 2007, 67, 1660-1669. [CrossRef] [PubMed]
35. Tetsu, O., McCormick, F. β-Catenin regulates expression of cyclinD1 in colon carcinoma cells. Nature 1999, 398, 422-426. [PubMed]
36. Chandra, S.H., Wacker, I., Appelt, U.K., Behrens, J., Schneikert, J. A common role for various human truncated adenomatous polyposis coli isoforms in the control of β-catenin activity and cell proliferation. PLoS ONE 2012, 7, e34479. [CrossRef] [PubMed]
37. Violette, S., Poulain, L., Dussaulx, E., Pepin, D., Faussat, A.M., Chambaz, J., Lacorte, J.M., Staedel, C., Lesuffleur, T. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of BCL-2 and BCL-xL in addition to BAX and p53 status. Int. J. Cancer 2002, 98, 498-504. [CrossRef] [PubMed]
38. LaBonte, M.J., Wilson, P.M., Fazzone, W., Russell, J., Louie, S.G., El-Khoueiry, A., Lenz, H.J., Ladner, R.D. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 2011, 71, 3635-3648. [CrossRef] [PubMed]
39. Liu, Y., Mallampalli, R.K. Small molecule therapeutics targeting F-box proteins in cancer. Semin. Cancer Biol. 2016, 36, 105-119. [CrossRef] [PubMed]
40. Holland, T.A., Elder, J., McCloud, J.M., Hall, C., Deakin, M., Fryer, A.A., Elder, J.B., Hoban, P.R. Subcellular localisation of cyclin D1 protein in colorectal tumours is associated with p21WAF1/CIP1 expression and correlates with patient survival. Int. J. Cancer 2001, 95, 302-306. [CrossRef]
41. Bahnassy, A.A., Zekri, A.R., El-Houssini, S., El-Shehaby, A.M., Mahmoud, M.R., Abdallah, S., El-Serafi, M. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol. 2004, 23, 22-24. [CrossRef] [PubMed]
42. Li, Y., Wei, J., Xu, C., Zhao, Z., You, T. Prognostic significance of cyclin D1 expression in colorectal cancer: A meta-analysis of observational studies. PLoS ONE 2014, 9, e94508. [CrossRef] [PubMed]
43. Biliran, H., Jr., Wang, Y., Banerjee, S., Xu, H., Heng, H., Thakur, A., Bollig, A., Sarkar, F.H., Liao, J.D. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin. Cancer Res. 2005, 11, 6075-6086. [CrossRef] [PubMed]
44. Shan, J., Zhao, W., Gu, W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol. Cell 2009, 36, 469-476. [CrossRef] [PubMed]
45. Davis, M.I., Pragani, R., Fox, J.T., Shen, M., Parmar, K., Gaudiano, E.F., Liu, L., Tanega, C., McGee, L., Hall, M.D., et al. Small molecule inhibition of the ubiquitin-specific protease USP2 accelerates cyclin D1 degradation and leads to cell cycle arrest in colorectal cancer and mantle cell lymphoma models. J. Biol. Chem. 2016. [CrossRef] [PubMed]
46. Kwak, Y.T., Li, R., Becerra, C.R., Tripathy, D., Frenkel, E.P., Verma, U.N. IκB kinase α regulates subcellular distribution and turnover of cyclin D1 by phosphorylation. J. Biol. Chem. 2005, 280, 33945-33952. [CrossRef] [PubMed]
47. Eo, H.J., Park, G.H., Song, H.M., Lee, J.W., Kim, M.K., Lee, M.H., Lee, J.R., Koo, J.S., Jeong, J.B. Silymarin induces cyclin D1 proteasomal degradation via its phosphorylation of threonine-286 in human colorectal cancer cells. Int. Immunopharmacol. 2015, 24, 1-6. [CrossRef] [PubMed]
48. Zou, Y., Ewton, D.Z., Deng, X., Mercer, S.E., Friedman, E. Mirk/Dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J. Biol. Chem. 2004, 279, 27790-27798. [CrossRef] [PubMed]
49. Agami, R., Bernards, R. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 2000, 102, 55-66. [CrossRef]
50. Su, J.C., Chang, J.H., Huang, J.W., Chen, P.P., Chen, K.F., Tseng, P.H., Shiau, C.W. Copper-obatoclax derivative complexes mediate DNA cleavage and exhibit anti-cancer effects in hepatocellular carcinoma. Chem. Biol. Interact. 2015, 228, 108-113. [CrossRef] [PubMed]
51. Koehler, B.C., Scherr, A.L., Lorenz, S., Urbanik, T., Kautz, N., Elssner, C., Welte, S., Bermejo, J.L., Jäger, D., Schulze-Bergkamen, H. Beyond cell death—Antiapoptotic BCL-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. PLoS ONE 2013, 8, e76446. [CrossRef] [PubMed]
52. Ligueros, M., Jeoung, D., Tang, B., Hochhauser, D., Reidenberg, M.M., Sonenberg, M. Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells. Br. J. Cancer 1997, 76, 21-28. [CrossRef] [PubMed]
53. Huang, Y.W., Wang, L.S., Chang, H.L., Ye, W., Sugimoto, Y., Dowd, M.K., Wan, P.J., Lin, Y.C. Effects of serum on (-)-gossypol-suppressed growth in human prostate cancer cells. Anticancer Res. 2006, 26, 3613-3620. [PubMed]
54. Wang, Z., Azmi, A.S., Ahmad, A., Banerjee, S., Wang, S., Sarkar, F.H., Mohammad, R.M. TW-37, a small-molecule inhibitor of BCL-2, inhibits cell growth and induces apoptosis in pancreatic cancer: Involvement of Notch-1 signaling pathway. Cancer Res. 2009, 69, 2757-2765. [CrossRef] [PubMed]
55. Ho, T.F., Peng, Y.T., Chuang, S.M., Lin, S.C., Feng, B.L., Lu, C.H., Yu, W.J., Chang, J.S., Chang, C.C. Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines. Toxicol. Appl. Pharmacol. 2009, 235, 253-260. [CrossRef] [PubMed]
56. Hsieh, H.Y., Shieh, J.J., Chen, C.J., Pan, M.Y., Yang, S.Y., Lin, S.C., Chang, J.S., Lee, A.Y., Chang, C.C. Prodigiosin down-regulates SKP2 to induce p27KIP1 stabilization and antiproliferation in human lung adenocarcinoma cells. Br. J. Pharmacol. 2012, 166, 2095-2108. [CrossRef] [PubMed]